Board

  • Dr Liz Dallimore (Chairman)

  • Prof Barry Clements

  • Dr Igor Gonda

  • Prof Anthony Hickey

Management

  • Dr Liz Dallimore : Executive Chairman

    Dr Liz Dallimore has deep experience in both biotechnology and management consulting with over 20 years’ experience across Australia and the UK. Liz is currently the CEO and Managing Director of Argenica Therapeutics (ASX:AGN), a clinical stage drug development company developing novel neuroprotective therapies to treat stroke and other neurological conditions. Prior to this she held senior roles with KPMG, Ernst & Young and PwC. Dr Dallimore is currently a non-executive Director of NERA, a Federal Government Growth Centre, AusBiotech, and the WA Chamber of Commerce and Industry. She holds a PhD in Neuroscience jointly completed at Oxford University and the University of Western Australia, an MBA from the Australian Graduate School of Management, and is a Member of the Australian Institute of Company Directors.

  • Mary-Ann Rennie : Chief Executive Officer

    Mary-Ann brings over 15 years of corporate operations, business development, contracts assurance and regulatory experience. Prior to Inspiring, Mary-Ann was COO at Emyria Limited, an ASX Listed Biotechnology and Clinical Services company where she was responsible for executing global pharmaceutical licensing deals and acquisitions for the company, as well as day to day operations. Prior to that Many-Ann was head of Business Development for TGA and FDA licensed pharmaceutical manufacturing Company, Wild Child. She has international experience spending 6 years working in Europe and has also held positions at both PwC and KPMG. Mary-Ann has a Bachelor of Commerce and a Bachelor of Science from the University of Western Australia. Mary-Ann is also a graduate of the Australian Institute of Company Directors.

  • Prof Barry Clements ; Founder & Chief Scientific Officer

    Professor Barry Clements has 35 years of respiratory clinical and research experience including previous device inventions and early phase drug development, including the founder of Respirion Pharmaceuticals, which recently raised AU$24M in Australia. He has conducted or been the Principal Investigator in many investigator-initiated and sponsored early and late phase clinical trials. He is an experienced well-respected clinical respiratory physician with many peer review presentations and publications and has membership with national and international respiratory, cystic fibrosis and inhalation aerosol and drug delivery societies. Professor Clements is also an Honorary Research Fellow at Telethon Kids Institute.

  • Ashley Schoof : Operations Manager

    Ashley has had significant experience in the development and commercialisation of early-stage life sciences innovation. Ashley is also currently a Commercialisation Officer at the Telethon Kids Institute, and has responsibility for identifying, protecting and commercialising intellectual property from Telethon Kids. In this role, Ashley has supported the founding of multiple spin out companies from Telethon Kids, including the raising of over $20m in capital and non-dilutive funding to support these companies. Ashley is managing operations for Inspiring, including leading the engagement with device development, regulatory and quality consultants.

Scientific Advisory Board

  • Dr Igor Gonda (Chair)

    Dr Igor Gonda, has over 40 years of experience in the research and development of inhaled therapies in academia and industry in Australia, UK and USA. He is the Founder and CEO of Respidex, a San Francisco-based consulting company providing technical and regulatory advice. Dr Gonda has held a variety of executive positions in US and Australian pharmaceutical and biotech companies.
    His research focus has been primarily in the area of drugs and biologics administered to the lung and nose, with research conducted in both industry and universities in England, Australia and the US. He is a Director of Inspiring Holdings Pty Ltd and the Chair of its SAB.

  • Prof Anthony Hickey

    Dr. Hickey is a Distinguished Fellow, at RTI International, Professor Emeritus of Pharmacoengineering and Molecular Pharmaceutics of the Eshelman School of Pharmacy, and Adjunct Professor of Biomedical Engineering of the School of Medicine at the University of North Carolina at Chapel Hill. He is founder (and formerly President and CEO) of Cirrus Pharmaceuticals, Inc.; founder (formerly CSO) of Oriel Therapeutics, Inc,; CEO of Astartein, LLC. and; Scientific Advisor to TFF Pharmaceuticals Inc.; Chair of the USP Joint Sub-Committee on Nanotechnology, Member of the USP Pharmaceutical Dosage Forms Expert Committee (DFEC) and Aerosols Sub-Committee of the DFEC of the United States Pharmacopeia. He conducts multidisciplinary research programs in the field of pulmonary drug and vaccine delivery for the treatment and prevention of a variety of diseases.

  • Prof Steve Stick

    Professor Steve Stick is the Northern Star Professor of Children’s Respiratory Health Research at Telethon Kids Institute. Professor Stick is a career clinician and clinical researcher, holds a NHMRC Practitioner Fellowship and is a Fellow of the Australian Academy of Health and Medical Science. Prof Stick was head of the Department of Respiratory and Sleep Medicine at Princess Margaret Hospital for Children from 1998-2016. In 2015 he was awarded the Richard Talamo Distinguished Clinical Achievement Award, the highest research award of the US Cystic Fibrosis Foundation. Prof Stick has had continuous research funding from the NHMRC since 1997 and currently holds over $14m in competitive research funding from national and international sources. His research focus has been the earliest manifestations of chronic respiratory diseases such as asthma and cystic fibrosis and developing interventions to prevent long term lung damage.

  • Prof Paul Young

    Professor Paul Young has more than 25 years experience in industry and academia, entrepreneurship, business creation and strategic development. Prof Young has held the Inaugural Chair of Commercialisation in the Faculty of Medicine and Health at the University of Sydney and was the Deputy Executive Director of the Woolcock Institute of Medical Research, the top ranked Medical Research Institute globally in respiratory medicine. He has established a number of successful SMEs including Nanopharm Ltd, OzUK Ltd, Pulmatix Pty Ltd, and has worked on numerous products that have come to market with scientific specialty in the area of pharmaceutical product development.